What can we help you find?
The European Committee for Medicinal Products for Human Use Backs Generic Lacosamide UCB for Partial-Onset Seizures
ResearchLacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.Neuroimmunology of Status Epilepticus
ResearchThere is urgent need for novel therapies for refractory SE that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Preclinical and clinical evidence encourage consideration of specific anti-inflammatory treatments for controlling SE and its consequences in patients.Precision Medicine for Genetic Epilepsy on the Horizon: Recent Advances, Present Challenges, and Suggestions for Continued Progress
ResearchThe genetic basis of many epilepsies is increasingly understood, giving rise to the possibility of precision treatments tailored to specific genetic etiologies. Despite this, current medical therapy for most epilepsies remains imprecise, aimed primarily at empirical seizure reduction rather than targeting specific disease processes.Anterior Nucleus of the Thalamus Deep Brain Stimulation Versus Temporal Lobe Responsive Neurostimulation for Temporal Lobe Epilepsy
ResearchBased on the promising results of randomized controlled trials, deep brain stimulation (DBS) and responsive neurostimulation (RNS) are increasingly used in the treatment of patients with drug-resistant epilepsy. Drug-resistant temporal lobe epilepsy (TLE) is an indication for either DBS of the anterior nucleus of the thalamus (ANT) or temporal lobe (TL) RNS, but there are no studies that directly compare seizure benefits and adverse effects associated with these therapies in this patient population.
Our Mission
Our mission is to fund breakthrough research that will transform the lives of people living with epilepsy as we lead the search for a cure.Effectiveness of Zonisamide (Zonegran®) in Childhood Refractory Epilepsy
ResearchZNS is an effective and reliable option as an add-on therapy in paediatric refractory epilepsy, especially in focal epilepsy. It can also be considered for treatment in TSC patients.
Fine-Tuning the 3’UTR as a Novel Therapeutic Strategy for Genetic Developmental and Epileptic Encephalopathies
Grants AwardedThe goal of this project is to develop a novel Antisense Oligonucleotide (ASO) strategy to treat DEE syndromes by changing how certain genes are processed within the cell.
Characterization of Functional Rescue in iPS Cell-derived Neuronal Models of KCNT1 and SCN8A Developmental Epileptic Encephalopathies
Grants AwardedThey will then test novel antisense oligonucleotides (ASOs) targeting each gene and investigate whether ASOs targeting KCNT1 can rescue the electrical properties of SCN8A and vice versa.